Company intelligence / Profile preview

Actithera

Cambridge, Massachusetts, United Statesm-ventures.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Actithera has developed a proprietary radiotherapeutic platform that links radioactive isotopes to small molecule or peptide carriers designed for rapid, specific, and persistent delivery into tumors while sparing healthy tissue. Their lead program targets FAP with preclinical data showing superior tumor uptake/retention compared to benchmarks. The company aims to bring its first program through IND-enabling studies toward Phase I/II proof-of-concept trials by late 2025 or beyond.

Therapeutic areas: Oncology
Modalities: Small moleculesPeptidesRadiotherapeutics (radioactive isotopes linked to targeting molecules)Theranostics
Industry: Biotech

Partnerships

Exclusive option agreement to in-license complementary technology; four academic collaborations signed as of early/mid 2025.

Beyond the preview

Go deeper on Actithera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actithera.

Explore the full profile